Article Information
History
- January 20, 2023.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Author Information
- Patrick DMC Katoto1,2,3,*,
- Mireille AM Kakubu4,
- Jacques L. Tamuzi2,
- Amanda S. Brand2,
- Adaeze Ayuk5,
- Liliane N. Byamungu6,
- Charles S. Wiysonge2,7,8 and
- Glenda Gray1
- 1Office of the President and CEO, South African Medical Research Council, Cape Town, South Africa
- 2Centre for Evidence-based Health Care, Division of Epidemiology and Biostatistics, Department of Global Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
- 3Centre for Tropical Diseases and Global Health, Department of Medicine, Catholic University of Bukavu, DR Congo
- 4Ministry of Health and Social Services of Namibia, Windhoek, Namibia
- 5Department of Paediatrics and Child Health, University of Nigeria Teaching Hospital, Enugu, Nigeria
- 6Department of Paediatric, Faculty of Medicine and Health Sciences, University of KwaZulu-Natal, Durban, South Africa
- 7Cochrane South Africa, South African Medical Research Council, Cape Town, South Africa
- 8HIV and other Infectious Diseases Research Unit, South African Medical Research Council, Durban, South Africa
- ↵*Corresponding author: Associate Professor Patrick DMC KATOTO, MD, MSC, PhD
, Office of the President and CEO, South African Medical Research Council, Francie van Zijl Drive, Parow Valley, Cape Town 7501, South Africa, Email: katoto{at}sun.ac.za, Tel: +27 21 9380340
Posted January 20, 2023.
Immunogenicity, Safety and Effectiveness of COVID-19 Pfizer-BioNTech (BNT162b2) mRNA Vaccination in Immunocompromised Adolescents and Young Adults: A systematic Review and Meta-Analyses
